The genetic diagnostics company announced the pricing of a common stock offering that suggests there's solid demand for shares.
News & Analysis: Adaptive Biotechnologies Corporation
It's an inevitable step in the evolution of healthcare -- and one that could help Illumina grow into its premium valuation.
There's plenty of untapped potential left in genomics, but there are quite a few other omics investors need to know about heading into 2020.
Is Wall Street's initial excitement giving way to more realistic expectations?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Depending on one customer for too much revenue is generally a red flag, but the intentional growth strategy of Personalis is worth paying closer attention to.
The diagnostic company reported second-quarter 2019 operating results, but shares tumbled in early September.
This natural gas stock, blood diagnostic company, and gold miner have caught the eye of some of the top investors.
Despite a strong day for the market, these stocks lagged behind.